Photodynamic Therapy Upregulates Expression of HIF-1α and PD-L1 in Related Pathways and Its Clinical Relevance in Non-small-cell Lung Cancer

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2024 Apr 12

PMID 38609977

Authors

Wen Sun

Yuan Cheng

Xiaoyu Ma

Zhou Jin

Qi Zhang

Guangfa Wang

Affiliations

Soon will be listed here.

Abstract

Background: Photodynamic therapy (PDT) is a promising interventional treatment approach that contributes to antitumor immunity. It has been reported that PDT can enhance the effectiveness of immune checkpoint inhibitors (ICIs), but its mechanism is yet unclear. Herein, we implemented bioinformatics analysis to detect common pathways and potential biomarkers in non-small cell lung cancer (NSCLC), PDT, and NSCLC immunotherapy to investigate potential links between PDT, immunotherapy and NSCLC, and their clinical impact.

Methods: Differentially expressed genes in NSCLC- and NSCLC immunotherapy-related data in the GEO database were intersected with PDT-related genes in the GeneCards database to obtain candidate genes and shared pathways. Enrichment analysis and protein-protein interaction were established to identify key genes in functionally enriched pathways. The expression profiles and the prognostic significance of key genes were depicted.

Results: Bioinformatics analysis showed that HIF-1α was screened as a prognostic gene in hypoxia, HIF-1, and PD-L1-related signaling pathways, which was associated with clinical response in NSCLC patients after PDT and immunotherapy. In vivo experiments showed that PDT could inhibit tumor growth and upregulate HIF-1α and PD-L1 expressions in NSCLC tissues with a positive correlation, which might influence the blocking activity of ICIs on the HIF-1, and PD-L1-related signaling pathways.

Conclusions: PDT might improve the clinical response of ICIs by upregulating tumor HIF-1α and PD-L1 expressions in NSCLC.

References

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

Volm M, Koomagi R . Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 2000; 20(3A):1527-33. View

Dolmans D, Fukumura D, Jain R . Photodynamic therapy for cancer. Nat Rev Cancer. 2003; 3(5):380-7. DOI: 10.1038/nrc1071. View

Korbecki J, Siminska D, Gassowska-Dobrowolska M, Listos J, Gutowska I, Chlubek D . Chronic and Cycling Hypoxia: Drivers of Cancer Chronic Inflammation through HIF-1 and NF-κB Activation: A Review of the Molecular Mechanisms. Int J Mol Sci. 2021; 22(19). PMC: 8509318. DOI: 10.3390/ijms221910701. View

Cramer G, Moon E, Cengel K, Busch T . Photodynamic Therapy and Immune Checkpoint Blockade. Photochem Photobiol. 2020; 96(5):954-961. DOI: 10.1111/php.13300. View

Maeding N, Verwanger T, Krammer B . Boosting Tumor-Specific Immunity Using PDT. Cancers (Basel). 2016; 8(10). PMC: 5082381. DOI: 10.3390/cancers8100091. View

Greijer A, van der Wall E . The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004; 57(10):1009-14. PMC: 1770458. DOI: 10.1136/jcp.2003.015032. View

Muz B, de la Puente P, Azab F, Azab A . The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2016; 3:83-92. PMC: 5045092. DOI: 10.2147/HP.S93413. View

Tzouvelekis A, Antoniou K, Kreuter M, Evison M, Blum T, Poletti V . The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Res. 2021; 7(1). PMC: 7837280. DOI: 10.1183/23120541.00529-2020. View

10.

Zhou F, Qiao M, Zhou C . The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol. 2020; 18(2):279-293. PMC: 8027847. DOI: 10.1038/s41423-020-00577-5. View

11.

Alzeibak R, Mishchenko T, Shilyagina N, Balalaeva I, Vedunova M, Krysko D . Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. J Immunother Cancer. 2021; 9(1). PMC: 7802670. DOI: 10.1136/jitc-2020-001926. View

12.

Wang Y, Xie Y, Li J, Peng Z, Sheinin Y, Zhou J . Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy. ACS Nano. 2017; 11(2):2227-2238. PMC: 5332348. DOI: 10.1021/acsnano.6b08731. View

13.

Karampitsakos T, Galaris A, Chrysikos S, Papaioannou O, Vamvakaris I, Barbayianni I . Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis. Respir Res. 2023; 24(1):279. PMC: 10648728. DOI: 10.1186/s12931-023-02551-x. View

14.

Yohena T, Yoshino I, Takenaka T, Kameyama T, Ohba T, Kuniyoshi Y . Upregulation of hypoxia-inducible factor-1alpha mRNA and its clinical significance in non-small cell lung cancer. J Thorac Oncol. 2009; 4(3):284-90. DOI: 10.1097/JTO.0b013e31819852d5. View

15.

Doroshow D, Bhalla S, Beasley M, Sholl L, Kerr K, Gnjatic S . PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 18(6):345-362. DOI: 10.1038/s41571-021-00473-5. View

16.

Hu L, Cao Z, Ma L, Liu Z, Liao G, Wang J . The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy. Biomaterials. 2019; 223:119469. DOI: 10.1016/j.biomaterials.2019.119469. View

17.

Tomayko M, Reynolds C . Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989; 24(3):148-54. DOI: 10.1007/BF00300234. View

18.

Wang D, Wang T, Liu J, Yu H, Jiao S, Feng B . Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy. Nano Lett. 2016; 16(9):5503-13. DOI: 10.1021/acs.nanolett.6b01994. View

19.

Giatromanolaki A, Koukourakis M, Sivridis E, Turley H, Talks K, Pezzella F . Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001; 85(6):881-90. PMC: 2375073. DOI: 10.1054/bjoc.2001.2018. View

20.

Wan J, Wu W, Che Y, Kang N, Zhang R . Low dose photodynamic-therapy induce immune escape of tumor cells in a HIF-1α dependent manner through PI3K/Akt pathway. Int Immunopharmacol. 2015; 28(1):44-51. DOI: 10.1016/j.intimp.2015.05.025. View